Tom Insel

Tom Insel’s role in the book is that of an institutional voice reconsidering how mental illness is classified and treated. Identified as the former director of the National Institute of Mental Health, he helps shift the discussion from whether one treatment can serve several diagnoses to whether the diagnoses themselves divide experience too neatly. His contribution is not a claim that psychedelic therapy has been proved; it is an argument that the categories through which psychiatry understands illness may not map cleanly onto reality.

Institutional position and the treatment crisis

The book introduces Insel amid a broader account of a mental-health system described as badly strained. Depression affects nearly one in ten Americans and is the leading cause of disability worldwide, yet the available pharmacological options are portrayed as limited: existing antidepressants have lost effectiveness for many, and pharmaceutical companies have pulled back from developing drugs directed at the central nervous system. The system reaches only a fraction of people with mental disorders, while cost, stigma, and disappointing treatment experiences discourage others from seeking care. The account also notes nearly 43,000 suicides a year in the United States and that only about half of those who die by suicide have received mental-health treatment. In that setting, Insel’s former leadership of the National Institute of Mental Health gives weight to his intervention, but the book does not present him as offering a personal history or as a participant in the clinical trials under discussion. His importance here is interpretive: he supplies a way to understand why a therapy that appears relevant to more than one diagnosis might not be an anomaly. The argument bears on the structure of psychiatry as well as on the prospects for a particular treatment.

Diagnostic boundaries and shared mechanisms

Insel says that the diagnostic categories in the Diagnostic and Statistical Manual of Mental Disorders do not reflect reality as neatly as their official divisions suggest. The boundaries between conditions, he argues, are to some extent arbitrary and shift between editions; they also serve the practical needs of the insurance industry. This does not mean that distress is unreal. Rather, it questions whether a classification system designed to sort conditions can be mistaken for a faithful map of how mental suffering is organized. His alternative emphasis is continuity. Insel points to the overlap among disorders and to the fact that selective serotonin reuptake inhibitors, when effective, can be used for conditions beyond depression, including anxiety and obsessive-compulsive disorder. Such cross-diagnostic usefulness suggests that different named conditions may share underlying processes. The book places this view alongside examples of depression, addiction, and anxiety occurring together, and of depression and anxiety being understood as responses to past and anticipated loss. Together, these examples make diagnostic borders appear less like walls than distinctions drawn across related forms of suffering. That perspective reframes the question of why psychedelic therapies are being investigated for several indications. The book cautions that reported successes remain signals rather than definitive proof: these treatments have not yet demonstrated their effectiveness in large populations. Insel’s point is more limited and more structural. If one approach appears promising across conditions, that breadth need not be dismissed as implausible, because the conditions may overlap more than the diagnostic labels acknowledge. It is a reason to investigate common mechanisms, not a declaration that the conditions are identical or that the treatment is established.

Psychedelic therapy and the mind–brain divide

The book sets Insel’s comments within a debate over what psychiatric treatment should address. One account of the field describes a long conflict between biologically based treatment and psychodynamic approaches, framed as a choice between a disorder of chemistry and a loss of meaning. Psychedelic therapy is proposed as a possible meeting point: a drug is administered, but its effects are inseparable from an experience shaped by the participant’s expectations, the treatment environment, and the guiding therapist. Insel’s comments about diagnostic continua support this wider questioning of tidy separations, though the book does not attribute the proposed synthesis of biological and psychodynamic treatment to him. The difficulty of studying psychedelics sharpens the issue. Participants and guides can often tell whether psilocybin or a placebo has been given, making conventional blinding difficult. Researchers must also contend with the influence of set and setting, which cannot easily be isolated from the drug’s effects. The treatment therefore challenges methods built around separating a single chemical variable from its context. In the book’s account, the question is not simply whether a molecule changes symptoms, but how pharmacology, psychotherapy, expectation, and experience combine. Insel’s presence lends this debate institutional reach without resolving it. His skepticism toward rigid diagnostic divisions makes room for inquiry into shared processes, while the book maintains that promising results are not yet proof of a cure. His significance lies in that balance: he helps make a broad therapeutic hypothesis intelligible, while leaving its evidence, mechanisms, and clinical value open to testing.